Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 64.05
-3.15 (-4.69%)
Sep 10, 2026, 11:59 AM HKT
Shanghai Henlius Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,435 | 6,667 | 5,724 | 5,395 | 3,215 | 1,682 | |
Revenue Growth | 28.24% | 16.46% | 6.11% | 67.82% | 91.07% | 186.34% |
Cost of Revenue | 1,882 | 1,682 | 1,540 | 1,476 | 844.62 | 522.75 |
Gross Profit | 5,554 | 4,985 | 4,185 | 3,919 | 2,370 | 1,160 |
Selling, General & Admin | 2,907 | 2,642 | 2,288 | 2,138 | 1,403 | 800.87 |
Research & Development | 1,756 | 1,515 | 1,035 | 1,119 | 1,395 | 1,024 |
Operating Expenses | 4,665 | 4,168 | 3,318 | 3,266 | 2,999 | 1,825 |
Operating Income | 888.99 | 817.12 | 866.5 | 652.95 | -628.53 | -665.25 |
Interest Expense | -100.01 | -102.49 | -122.89 | -110.54 | -105.67 | -84.82 |
Interest & Investment Income | 14.98 | 18.79 | 21.7 | 8.15 | 3.57 | 2.69 |
Currency Exchange Gain (Loss) | - | - | 8.14 | -1.42 | 32.92 | - |
Other Non Operating Income (Expenses) | 101.01 | 67.47 | 72.43 | 20.44 | 202.97 | -209.36 |
EBT Excluding Unusual Items | 904.97 | 800.89 | 845.88 | 569.58 | -494.73 | -956.74 |
Gain (Loss) on Sale of Investments | - | - | - | - | -199.15 | - |
Gain (Loss) on Sale of Assets | 10.83 | 10.83 | - | - | - | - |
Pretax Income | 915.81 | 811.72 | 845.88 | 569.58 | -693.89 | -956.74 |
Income Tax Expense | 48.45 | -15.32 | 25.41 | 23.56 | 1.37 | 27.31 |
Earnings From Continuing Operations | 867.35 | 827.04 | 820.47 | 546.02 | -695.26 | -984.05 |
Net Income | 867.35 | 827.04 | 820.47 | 546.02 | -695.26 | -984.05 |
Net Income to Common | 867.35 | 827.04 | 820.47 | 546.02 | -695.26 | -984.05 |
Net Income Growth | 5.22% | 0.80% | 50.26% | - | - | - |
Shares Outstanding (Basic) | 544 | 543 | 543 | 543 | 542 | 539 |
Shares Outstanding (Diluted) | 548 | 546 | 543 | 543 | 542 | 539 |
Shares Change | 0.83% | 0.45% | 0.02% | 0.25% | 0.59% | 1.75% |
EPS (Basic) | 1.60 | 1.52 | 1.51 | 1.01 | -1.28 | -1.83 |
EPS (Diluted) | 1.58 | 1.51 | 1.51 | 1.00 | -1.28 | -1.83 |
EPS Growth | 4.16% | 0.03% | 50.96% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 994.25 | 1,078 | 574.25 | 396.65 | -370.04 |
Free Cash Flow Per Share | - | 1.82 | 1.98 | 1.06 | 0.73 | -0.69 |
Gross Margin | 74.69% | 74.77% | 73.10% | 72.64% | 73.73% | 68.93% |
Operating Margin | 11.96% | 12.26% | 15.14% | 12.10% | -19.55% | -39.54% |
Profit Margin | 11.67% | 12.41% | 14.33% | 10.12% | -21.63% | -58.49% |
Free Cash Flow Margin | - | 14.91% | 18.83% | 10.64% | 12.34% | -21.99% |
EBITDA | 1,224 | 1,163 | 1,162 | 932.58 | -419.93 | -518.3 |
EBITDA Margin | 16.46% | 17.45% | 20.29% | 17.29% | -13.06% | -30.80% |
D&A For EBITDA | 335.07 | 346.05 | 295.29 | 279.63 | 208.6 | 146.95 |
EBIT | 888.99 | 817.12 | 866.5 | 652.95 | -628.53 | -665.25 |
EBIT Margin | 11.96% | 12.26% | 15.14% | 12.10% | -19.55% | -39.54% |
Effective Tax Rate | 5.29% | - | 3.00% | 4.14% | - | - |